The Gross Law Firm Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 – CAPR

Core Viewpoint - The Gross Law Firm is notifying shareholders of Capricor Therapeutics, Inc. regarding a potential class action lawsuit due to misleading statements related to the company's drug deramiocel for treating cardiomyopathy associated with Duchenne muscular dystrophy [1][3]. Summary by Relevant Sections Company Information - Capricor Therapeutics, Inc. is involved in developing cell therapy candidates, specifically deramiocel, aimed at treating cardiomyopathy linked to Duchenne muscular dystrophy [3]. Allegations - The complaint alleges that Capricor provided investors with misleading information about deramiocel's potential to secure a Biologics License Application (BLA) from the FDA while concealing adverse facts regarding the drug's safety and efficacy data from its Phase 2 HOPE-2 trial [3]. - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the BLA due to insufficient evidence of effectiveness and the need for additional clinical data, Capricor's stock price fell from $11.40 to $7.64 per share [3]. Class Action Details - The class period for the lawsuit is defined as October 9, 2024, to July 10, 2025, with a deadline for shareholders to register for the class action set for September 15, 2025 [4]. - Shareholders who register will receive updates on the case's progress through a portfolio monitoring software [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5].